BACKGROUND AND PURPOSE: Data from randomized trials assert that asymptomatic patients undergoing carotid endarterectomy (CEA) must live 3 to 5 years to realize the benefit of surgery. We examined how commonly CEA is performed among asymptomatic patients with limited life expectancy. METHODS: Within the American College of Surgeons National Quality Improvement Project we identified 8 conditions associated with limited life expectancy based on survival estimates using external sources. We then compared rates of 30-day stroke, death, and myocardial infarction after CEA between asymptomatic patients with and without life-limiting conditions. RESULTS: Of 12,631 CEAs performed in asymptomatic patients, 2525 (20.0%) were in patients with life-limiting conditions or diagnoses. The most common conditions were severe chronic obstructive pulmonary disease and American Society of Anesthesiologists Class IV designation. Patients with life-limiting conditions had significantly higher rates of perioperative complications, including stroke (1.8% versus 0.9%, P<0.001), death (1.4% versus 0.3%, P<0.001), and stroke/death (2.9% versus 1.1%, P<0.001). Even after adjustment for other comorbidities, patients with life-limiting conditions were nearly 3 times more likely to experience perioperative stroke or death than those without these conditions (OR, 2.8; 95% CI, 2.1-3.8; P<0.001). CONCLUSION: CEA is performed commonly in asymptomatic patients with life-limiting conditions. Given the high rates of postoperative stroke/death in these patients as well as their limited life expectancy, the net benefit of CEA in this population remains uncertain. Health policy research examining the role of CEA in asymptomatic patients with life-limiting conditions is necessary and may serve as a potential source for significant healthcare savings in the future.
BACKGROUND AND PURPOSE: Data from randomized trials assert that asymptomatic patients undergoing carotid endarterectomy (CEA) must live 3 to 5 years to realize the benefit of surgery. We examined how commonly CEA is performed among asymptomatic patients with limited life expectancy. METHODS: Within the American College of Surgeons National Quality Improvement Project we identified 8 conditions associated with limited life expectancy based on survival estimates using external sources. We then compared rates of 30-day stroke, death, and myocardial infarction after CEA between asymptomatic patients with and without life-limiting conditions. RESULTS: Of 12,631 CEAs performed in asymptomatic patients, 2525 (20.0%) were in patients with life-limiting conditions or diagnoses. The most common conditions were severe chronic obstructive pulmonary disease and American Society of Anesthesiologists Class IV designation. Patients with life-limiting conditions had significantly higher rates of perioperative complications, including stroke (1.8% versus 0.9%, P<0.001), death (1.4% versus 0.3%, P<0.001), and stroke/death (2.9% versus 1.1%, P<0.001). Even after adjustment for other comorbidities, patients with life-limiting conditions were nearly 3 times more likely to experience perioperative stroke or death than those without these conditions (OR, 2.8; 95% CI, 2.1-3.8; P<0.001). CONCLUSION: CEA is performed commonly in asymptomatic patients with life-limiting conditions. Given the high rates of postoperative stroke/death in these patients as well as their limited life expectancy, the net benefit of CEA in this population remains uncertain. Health policy research examining the role of CEA in asymptomatic patients with life-limiting conditions is necessary and may serve as a potential source for significant healthcare savings in the future.
Authors: S F Khuri; J Daley; W Henderson; K Hur; J O Gibbs; G Barbour; J Demakis; G Irvin; J F Stremple; F Grover; G McDonald; E Passaro; P J Fabri; J Spencer; K Hammermeister; J B Aust Journal: J Am Coll Surg Date: 1997-10 Impact factor: 6.113
Authors: J Daley; S F Khuri; W Henderson; K Hur; J O Gibbs; G Barbour; J Demakis; G Irvin; J F Stremple; F Grover; G McDonald; E Passaro; P J Fabri; J Spencer; K Hammermeister; J B Aust; C Oprian Journal: J Am Coll Surg Date: 1997-10 Impact factor: 6.113
Authors: J Biller; W M Feinberg; J E Castaldo; A D Whittemore; R E Harbaugh; R J Dempsey; L R Caplan; T F Kresowik; D B Matchar; J F Toole; J D Easton; H P Adams; L M Brass; R W Hobson; T G Brott; L Sternau Journal: Circulation Date: 1998-02-10 Impact factor: 29.690
Authors: J L Cronenwett; J D Birkmeyer; G B Nackman; M F Fillinger; F R Bech; R M Zwolak; D B Walsh Journal: J Vasc Surg Date: 1997-02 Impact factor: 4.268
Authors: E Christensen; P Schlichting; L Fauerholdt; C Gluud; P K Andersen; E Juhl; H Poulsen; N Tygstrup Journal: Hepatology Date: 1984 May-Jun Impact factor: 17.425
Authors: Jessica B Wallaert; Brian W Nolan; David H Stone; Richard J Powell; Jeremiah R Brown; Jack L Cronenwett; Philip P Goodney Journal: J Vasc Surg Date: 2015-10-01 Impact factor: 4.268
Authors: Jessica B Wallaert; Karina A Newhall; Bjoern D Suckow; Benjamin S Brooke; Min Zhang; Adrienne E Farber; Donald Likosky; Philip P Goodney Journal: Ann Vasc Surg Date: 2016-05-26 Impact factor: 1.466
Authors: Natalie D Sridharan; Rabih A Chaer; Bryan Boyuan Wu; Mohammad H Eslami; Michel S Makaroun; Efthymios D Avgerinos Journal: Ann Vasc Surg Date: 2017-07-06 Impact factor: 1.466
Authors: Jessica B Wallaert; Jack L Cronenwett; Daniel J Bertges; Andres Schanzer; Brian W Nolan; Randall De Martino; Jens Eldrup-Jorgensen; Philip P Goodney Journal: J Vasc Surg Date: 2013-03-07 Impact factor: 4.268
Authors: Adrienne E Faerber; Rebecca Horvath; Carey Stillman; Melissa L O'Connell; Amy L Hamilton; Karina A Newhall; Donald S Likosky; Philip P Goodney Journal: BMC Med Inform Decis Mak Date: 2015-03-24 Impact factor: 2.796